Ibrutinib: Phase II data

An open-label, U.S. Phase II trial in 13 MM patients with progressive disease after >=2 prior lines of therapy showed that once-daily 420 mg oral ibrutinib produced no partial or complete responses. Pharmacyclics said that several patients achieved stable disease and minor response. The company has expanded the trial, which is expected to enroll up to 164 patients, to evaluate once-daily 560 and 840 mg doses of ibrutinib as a single agent and in combination with dexamethasone at the 560 mg dose. Pharmacyclics said it does not intend to further evaluate the 420 mg dose of ibrutinib as a single agent in MM patients. Data will be presented at the American Society of Hematology meeting in Atlanta in December. ...